Targeting cytokines and signaling molecules related to immune pathways in atopic dermatitis: therapeutic implications and challenges
Although atopic dermatitis (AD) is primarily a Th2-driven disease, it shows high heterogeneity with additional variable contributions of the Th22, Th17, and Th1 pathways, depending on the subtype of the disease. Expanding knowledge and understanding of AD pathogenesis has promoted the development of...
Saved in:
| Published in | Archives of pharmacal research Vol. 45; no. 12; pp. 894 - 908 |
|---|---|
| Main Author | |
| Format | Journal Article |
| Language | English |
| Published |
Seoul
Pharmaceutical Society of Korea
01.12.2022
|
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | Although atopic dermatitis (AD) is primarily a Th2-driven disease, it shows high heterogeneity with additional variable contributions of the Th22, Th17, and Th1 pathways, depending on the subtype of the disease. Expanding knowledge and understanding of AD pathogenesis has promoted the development of numerous novel therapeutics that target cytokines and their signaling molecules, representatively, Janus kinases, involved in the underlying immune pathways, resulting in therapeutic success and failure. The first FDA approval was for the targeted biologic dupilumab. Although this proved the therapeutic relevance of targeting Th2 cytokines in moderate-to-severe forms of AD, it did not treat all patients, necessitating additional targeted therapeutics that modulate other cytokine pathways to resolve AD in all subtypes. Three more recently FDA-approved targeted therapeutics and several others that have been developed represent different targeted approaches directed to the Th2, Th22, Th17, or Th1 pathways. This review summarizes the main features and clinical outcomes of various approaches targeting cytokines and signaling molecules in these different pathways in view of both successful and failed cases, with a discussion of their therapeutic implications. In future, AD should be treated with more specific treatments reflecting the disease heterogeneity, but the current development of targeted therapeutics has faced some challenges in this context, which is also discussed. |
|---|---|
| AbstractList | Although atopic dermatitis (AD) is primarily a Th2-driven disease, it shows high heterogeneity with additional variable contributions of the Th22, Th17, and Th1 pathways, depending on the subtype of the disease. Expanding knowledge and understanding of AD pathogenesis has promoted the development of numerous novel therapeutics that target cytokines and their signaling molecules, representatively, Janus kinases, involved in the underlying immune pathways, resulting in therapeutic success and failure. The first FDA approval was for the targeted biologic dupilumab. Although this proved the therapeutic relevance of targeting Th2 cytokines in moderate-to-severe forms of AD, it did not treat all patients, necessitating additional targeted therapeutics that modulate other cytokine pathways to resolve AD in all subtypes. Three more recently FDA-approved targeted therapeutics and several others that have been developed represent different targeted approaches directed to the Th2, Th22, Th17, or Th1 pathways. This review summarizes the main features and clinical outcomes of various approaches targeting cytokines and signaling molecules in these different pathways in view of both successful and failed cases, with a discussion of their therapeutic implications. In future, AD should be treated with more specific treatments reflecting the disease heterogeneity, but the current development of targeted therapeutics has faced some challenges in this context, which is also discussed. |
| Author | Kim, Hyung-Ook |
| Author_xml | – sequence: 1 givenname: Hyung-Ook orcidid: 0000-0001-7700-1413 surname: Kim fullname: Kim, Hyung-Ook email: hyungook@konyang.ac.kr organization: Department of Clinical Medicinal Sciences, Konyang University |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/36462097$$D View this record in MEDLINE/PubMed |
| BookMark | eNp9kE9v1DAQxS3Uim4LX4AD8pFLwH9ie80NVbQgVeqlnC3Hmey6OHawHaG988FxSeHIYTTSmzdvNL9LdBZTBITeUPKeEqI-FMqYYh1hrWjPaMdeoB3VSnZc7eUZ2hEmeCeZ1BfospRHQrgUQrxEF1z2khGtdujXg80HqD4esDvV9N1HKNjGERd_iDY86XMK4NbQ9AzBVhhxTdjP8xoBL7Yef9pTwT5iW9PiHR4hz7b66stHXI-Q7QJrbbqfl-Bdm6S4XXBHGwLEA5RX6HyyocDr536Fvt18frj-0t3d3369_nTXOd6r2onBcasUs07o3hFHR2AD76l2sBdMCCkGMkyUaa2pGMFNzI7jnstxkrIng-BX6N2Wu-T0Y4VSzeyLgxBshLQWw1Qvue4p583KNqvLqZQMk1myn20-GUrME32z0TeNvvlD37C29PY5fx1mGP-t_MXdDHwzlDZqn2fzmNbcOJf_xf4GQeyVGA |
| CitedBy_id | crossref_primary_10_1021_acs_jafc_4c00205 crossref_primary_10_1007_s10875_023_01636_y crossref_primary_10_1016_j_jdcr_2023_04_019 |
| Cites_doi | 10.2147/ITT.S260370 10.1111/jdv.17218 10.1007/s40265-020-01335-7 10.1016/j.jdcr.2021.01.020 10.1056/NEJMoa1610020 10.1097/TP.0000000000000581 10.2340/00015555-3510 10.1146/annurev-immunol-032414-112123 10.2147/CCID.S295672 10.1016/j.jmb.2013.01.024 10.1016/j.jaip.2020.11.034 10.3389/fimmu.2019.02342 10.1111/exd.13911 10.1111/all.13954 10.3389/fmed.2021.638325 10.1016/j.jaci.2017.03.023 10.1093/eurheartj/ehu202 10.1016/j.jaci.2014.08.008 10.1016/j.jaci.2021.10.022 10.1016/j.aller.2018.06.008 10.1016/j.jaci.2011.02.010 10.1038/s41584-022-00767-7 10.1517/14712598.2016.1135898 10.1016/j.det.2021.12.002 10.1016/j.jaci.2018.08.02 10.1016/S0140-6736(22)01539-2 10.1007/s40265-017-0768-3 10.1111/all.14791 10.1016/j.jaci.2019.08.013 10.1016/j.jaci.2020.04.062 10.1038/nrd4624 10.4049/jimmunol.1600126 10.1016/j.jaci.2018.10.032 10.3390/ijms21041314 10.1016/j.jaci.2018.07.028 10.1016/j.eng.2020.06.029 10.1111/all.13239 10.3390/jcm11154431 10.3390/jcm11164639 10.1111/all.14050 10.1001/jamadermatol.2019.3336 10.1111/bjd.21776 10.1001/jamadermatol.2020.1406 10.1016/j.jid.2018.12.018 10.1016/j.jaci.2021.08.009 10.1111/bjd.19573 10.1016/j.jaad.2018.01.016 10.1111/cea.13954 10.1001/jamadermatol.2021.3023 10.25251/skin.6.supp.s29 10.1016/j.anai.2019.10.005 10.1007/s40265-021-01583-1 10.1056/NEJMoa2019380 10.3390/ijms222413655 10.1016/S0140-6736(20)30732-7 10.1016/j.jmb.2016.12.005 10.1111/j.1399-3038.2007.00586.x 10.1016/S0140-6736(17)31191-1 10.1016/j.jaad.2020.04.104 10.1056/nejmoa1917006 10.1016/j.jaci.2021.01.013 10.1016/j.anai.2019.03.033 10.1016/j.alit.2018.12.011 10.1001/jamadermatol.2022.0029 10.2340/00015555-3515 10.1016/S0140-6736(20)31286-1 10.1016/S0140-6736(22)01199-0 10.1016/j.jid.2019.03.636 10.1186/s13223-022-00652-8 10.4049/jimmunol.1800013 10.1093/intimm/dxy015 10.1016/j.jaci.2020.04.055 10.1007/s40257-021-00639-y 10.1007/s40257-018-0413-2 10.1016/j.jaci.2012.07.012 10.1111/exd.13533 10.2147/CCID.S165605 10.1016/S0140-6736(21)00589-4 10.1016/j.jaad.2020.06.054 10.1111/exd.14425 10.1016/j.alit.2021.10.004 10.1016/j.alit.2021.07.003 10.1016/j.bbrc.2018.08.064 10.1016/j.jaci.2012.02.020 10.1007/s40265-021-01638-3 10.1007/s40257-022-00684-1 10.1016/j.molmed.2022.04.010 10.1111/all.12339 10.3389/fimmu.2019.01293 10.1016/j.jaci.2017.01.011 10.1016/j.jaci.2016.06.010 10.1111/bjd.19574 10.3389/fped.2022.777992 10.1016/j.sder.2008.04.004 10.1111/j.1398-9995.2005.00791.x 10.1111/all.12184 10.1016/j.jid.2016.02.253 10.1038/s41573-021-00266-6 |
| ContentType | Journal Article |
| Copyright | The Pharmaceutical Society of Korea 2022. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. 2022. The Pharmaceutical Society of Korea. |
| Copyright_xml | – notice: The Pharmaceutical Society of Korea 2022. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. – notice: 2022. The Pharmaceutical Society of Korea. |
| DBID | NPM AAYXX CITATION 7X8 |
| DOI | 10.1007/s12272-022-01421-2 |
| DatabaseName | PubMed CrossRef MEDLINE - Academic |
| DatabaseTitle | PubMed CrossRef MEDLINE - Academic |
| DatabaseTitleList | PubMed |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine Pharmacy, Therapeutics, & Pharmacology |
| EISSN | 1976-3786 |
| EndPage | 908 |
| ExternalDocumentID | 10_1007_s12272_022_01421_2 36462097 |
| Genre | Journal Article Review |
| GrantInformation_xml | – fundername: Konyang University grantid: Research fund in 2021 funderid: http://dx.doi.org/10.13039/501100002511 – fundername: Konyang University grantid: Research fund in 2021 |
| GroupedDBID | --- -53 -56 -5G -BR -EM -Y2 -~C .86 .UV .VR 06C 06D 0R~ 0VY 1N0 2.D 203 23N 29~ 2J2 2JN 2JY 2KG 2KM 2LR 2VQ 2WC 2~H 30V 3SX 4.4 406 408 40D 40E 53G 5GY 5VS 67N 67Z 6J9 6NX 8TC 8UJ 95- 95. 95~ 96X 9ZL AAAVM AABHQ AABYN AAFGU AAHNG AAIAL AAJKR AAKSU AANXM AANZL AAPBV AARHV AARTL AATNV AATVU AAUYE AAWCG AAYFA AAYIU AAYQN AAYTO ABDZT ABECU ABFGW ABFTV ABHQN ABJNI ABJOX ABKAS ABKCH ABMNI ABMQK ABNWP ABPLI ABQBU ABSXP ABTEG ABTKH ABTMW ABWNU ABXPI ACBMV ACBRV ACBXY ACBYP ACGFO ACGFS ACHSB ACHXU ACIGE ACIPQ ACKNC ACMDZ ACMLO ACOKC ACOMO ACREN ACSNA ACTTH ACUDM ACVWB ACWMK ADHHG ADHIR ADINQ ADKNI ADKPE ADMDM ADOXG ADRFC ADTPH ADURQ ADYFF ADYOE ADZKW AEBTG AEEQQ AEFTE AEGAL AEGNC AEJHL AEJRE AEKMD AENEX AEOHA AEPYU AESKC AESTI AETLH AEVLU AEVTX AEXYK AFAFS AFGCZ AFLOW AFNRJ AFQWF AFWTZ AFYQB AFZKB AGAYW AGDGC AGGBP AGGDS AGJBK AGKHE AGMZJ AGQMX AGWIL AGWZB AGYKE AHAVH AHBYD AHKAY AHSBF AHYZX AIAKS AIIXL AILAN AIMYW AITGF AJBLW AJDOV AJRNO AJZVZ AKMHD AKQUC ALMA_UNASSIGNED_HOLDINGS ALWAN AMKLP AMTXH AMXSW AMYLF AMYQR AOCGG ARMRJ ASPBG AVWKF AXYYD AZFZN B-. BA0 BBWZM BDATZ BGNMA C1A CAG COF CS3 CSCUP DDRTE DNIVK DPUIP EBLON EBS EIOEI EJD EMOBN ESBYG F5P FEDTE FERAY FFXSO FIGPU FINBP FNLPD FRRFC FSGXE FWDCC G-Y G-Z GGCAI GGRSB GJIRD GNWQR GQ6 GQ7 GRRUI HF~ HG6 HMJXF HRMNR HVGLF HZ~ IJ- IKXTQ IWAJR IXC IXD I~X I~Z J-C J0Z JBSCW JZLTJ KOV KPH KVFHK LLZTM M4Y MA- MZR N2Q N9A NDZJH NF0 NPVJJ NQJWS NU0 O9- O93 O9G O9I O9J OVD P19 P2P PF0 PT4 PT5 QOK QOR QOS R89 R9I RHV RNI RNS ROL RPX RSV RZK S16 S1Z S26 S27 S28 S3A S3B SAP SBL SCLPG SDE SDH SHX SISQX SJN SNE SNPRN SNX SOHCF SOJ SPISZ SRMVM SSLCW SSXJD STPWE SZ9 SZN T13 T16 TEORI TSG TSK TUC U2A U9L UG4 UNUBA UOJIU UTJUX UZXMN VC2 VFIZW W48 WK6 WK8 YLTOR Z45 Z7U Z7V Z7W Z7X Z83 Z87 Z8O Z8P Z8Q Z91 ZMTXR ZOVNA ZZE ~A9 AACDK AAEOY AAHBH AAJBT AASML AAYZH ABAKF ACAOD ACDTI ACZOJ AEFQL AEMSY AFBBN AGQEE AGRTI AIGIU AJOOF H13 NPM SJYHP AAYXX ABQSL CITATION 7X8 |
| ID | FETCH-LOGICAL-c347t-5bc3a772ac594c0c1de2b3419ce8525565b0bf1299915decf2add836df6640b53 |
| IEDL.DBID | AGYKE |
| ISSN | 0253-6269 |
| IngestDate | Fri Oct 25 00:00:29 EDT 2024 Fri Dec 06 01:56:30 EST 2024 Wed Oct 16 00:40:18 EDT 2024 Sat Dec 16 12:06:50 EST 2023 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 12 |
| Keywords | Th1 pathways, Targeted therapeutics, Therapeutic implications Th22 Atopic dermatitis, Th2 Th17 |
| Language | English |
| License | 2022. The Pharmaceutical Society of Korea. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c347t-5bc3a772ac594c0c1de2b3419ce8525565b0bf1299915decf2add836df6640b53 |
| Notes | ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-3 content type line 23 ObjectType-Review-1 |
| ORCID | 0000-0001-7700-1413 |
| PMID | 36462097 |
| PQID | 2746394133 |
| PQPubID | 23479 |
| PageCount | 15 |
| ParticipantIDs | proquest_miscellaneous_2746394133 crossref_primary_10_1007_s12272_022_01421_2 pubmed_primary_36462097 springer_journals_10_1007_s12272_022_01421_2 |
| PublicationCentury | 2000 |
| PublicationDate | 2022-12-01 |
| PublicationDateYYYYMMDD | 2022-12-01 |
| PublicationDate_xml | – month: 12 year: 2022 text: 2022-12-01 day: 01 |
| PublicationDecade | 2020 |
| PublicationPlace | Seoul |
| PublicationPlace_xml | – name: Seoul – name: Korea (South) |
| PublicationTitle | Archives of pharmacal research |
| PublicationTitleAbbrev | Arch. Pharm. Res |
| PublicationTitleAlternate | Arch Pharm Res |
| PublicationYear | 2022 |
| Publisher | Pharmaceutical Society of Korea |
| Publisher_xml | – name: Pharmaceutical Society of Korea |
| References | RebaneAZimmermannMAabABaurechtHKoreckAKarelsonMAbramKMetsaluTPihlapMMeyerNFölster-HolstRNagyNKemenyLKingoKViloJIlligTAkdisMFrankeANovakNWeidingerSAkdisCAMechanisms of IFN-γ-induced apoptosis of human skin keratinocytes in patients with atopic dermatitisJ Allergy Clin Immunol2012129129713061:CAS:528:DC%2BC38Xks12jur0%3D10.1016/j.jaci.2012.02.020 BylundSKobyletzkiLBSvalstedtMSvenssonÅPrevalence and incidence of atopic dermatitis: a systematic reviewActa Derm Venereol20201000016010.2340/00015555-3510 MastraftsiSVrioniGBakakisMNicolaidouERigopoulosDStratigosAJGregoriouSAtopic dermatitis: striving for reliable biomarkersJ Clin Med20221146391:CAS:528:DC%2BB38Xit1yktLzN10.3390/jcm11164639 TsoiLCRodriguezEDegenhardtFBaurechtHWehkampUVolksNSzymczakSSwindellWRSarkarMKRajaKShaoSPatrickMGaoYUppalaRPerez WhiteBEGetsiosSHarmsPWMaverakisEElderJTFrankeAGudjonssonJEWeidingerSAtopic dermatitis is an IL-13-dominant disease with greater molecular heterogeneity compared to psoriasisJ Invest Dermatol2019139148014891:CAS:528:DC%2BC1MXks1Sgu7w%3D10.1016/j.jid.2018.12.018 SimpsonELPappKABlauveltAChuCYHongHCKatohNCalimlimBMThyssenJPChiouASBissonnetteRStein GoldLFWegzynCHuXLiuMLiuJTenorioARChuADGuttman-YasskyEEfficacy and safety of upadacitinib in patients with moderate to severe atopic dermatitis: analysis of follow-up data from the measure up 1 and measure up 2 randomized clinical trialsJAMA Dermatol202215840441310.1001/jamadermatol.2022.0029 ClinicalTrials.gov (2019b) Evaluation of the Efficacy and Safety of Lebrikizumab (LY3650150) in Moderate to Severe Atopic Dermatitis (ADvocate2). https://clinicaltrials.gov/ct2/show/NCT04178967?term=advocate-2&draw=2&rank=1. Accessed 15 Sep 2022 SimpsonELPallerASSiegfriedECBoguniewiczMSherLGooderhamMJBeckLAGuttman-YasskyEPariserDBlauveltAWeismanJLockshinBHultschTZhangQKamalMADavisJDAkinladeBStaudingerHHamiltonJDGrahamNMHPirozziGGadkariAEckertLStahlNYancopoulosGDRuddyMBansalAEfficacy and Safety of dupilumab in adolescents with uncontrolled moderate to severe atopic dermatitis: a phase 3 randomized clinical trialJAMA Dermatol2020156445610.1001/jamadermatol.2019.3336 ThijsJLStricklandIBruijnzeel-KoomenCAFMNierkensSGiovannoneBCsomorESellmanBRMustelinTSleemanMAde Bruin-WellerMSHerathADrylewiczJMayRDHijnenDMoving toward endotypes in atopic dermatitis: identification of patient clusters based on serum biomarker analysisJ Allergy Clin Immunol20171407307371:CAS:528:DC%2BC2sXnvVyktLk%3D10.1016/j.jaci.2017.03.023 SimpsonELBieberTGuttman-YasskyEBeckLABlauveltACorkMJSilverbergJIDeleuranMKataokaYLacourJPKingoKWormMPoulinYWollenbergASooYGrahamNMPirozziGAkinladeBStaudingerHMasteyVEckertLGadkariAStahlNYancopoulosGDArdeleanuMTwo phase 3 trials of dupilumab versus placebo in atopic dermatitisN Engl J Med2016375233523481:CAS:528:DC%2BC2sXhvVShtg%3D%3D10.1056/NEJMoa1610020 MizutaniYTakagiNNagataHInoueSInterferon-γ downregulates tight junction function, which is rescued by interleukin-17AExp Dermatol202130175417631:CAS:528:DC%2BB3MXitV2isL7P10.1111/exd.14425 GandhiNABennettBLGrahamNMPirozziGStahlNYancopoulosGDTargeting key proximal drivers of type 2 inflammation in diseaseNat Rev Drug Discov20161535501:CAS:528:DC%2BC2MXhs1Kqt7jP10.1038/nrd4624 ClinicalTrials.gov (2020) Safety and Efficacy of Lebrikizumab (LY3650150) in Combination with Topical Corticosteroid in Moderate-to-Severe Atopic Dermatitis (ADhere). https://clinicaltrials.gov/ct2/show/NCT04250337?term=adhere+lebrikizumab&draw=2&rank=1. Accessed 15 Sep 2022 MoyleMCevikbasFHardenJLGuttman-YasskyEUnderstanding the immune landscape in atopic dermatitis: the era of biologics and emerging therapeutic approachesExp Dermatol20192875676810.1111/exd.13911 YangNChenLShaoJJiangFLiuJLiZDupilumab with concomitant Janus kinase inhibitor: a novel treatment strategy for atopic dermatitis with poor response to dupilumabBr J Dermatol20221878288301:CAS:528:DC%2BB38XisVensb3I10.1111/bjd.21776 MasseyOSuphiogluCRecent advances in the inhibition of the IL-4 cytokine pathway for the treatment of allergen-induced asthmaInt J Mol Sci202122136551:CAS:528:DC%2BB38XhtlWktLg%3D10.3390/ijms222413655 ZhangDJHaoFQianTChengHXExpression of helper and regulatory t cells in atopic dermatitis: a meta-analysisFront Pediatr20221010.3389/fped.2022.777992 NomuraTKabashimaKAdvances in atopic dermatitis in 2019–2020: endotypes from skin barrier, ethnicity, properties of antigen, cytokine profiles, microbiome, and engagement of immune cellsJ Allergy Clin Immunol2021148145114621:CAS:528:DC%2BB38XovVWqs7w%3D10.1016/j.jaci.2021.10.022 SchühlenHPre-specified vs. post-hoc subgroup analyses: are we wiser before or after a trial has been performed?Eur Heart J2014352055205710.1093/eurheartj/ehu202 AkhavanARudikoffDAtopic dermatitis: systemic immunosuppressive therapySemin Cutan Med Surg2008271511551:CAS:528:DC%2BD1cXpt1WhsLY%3D10.1016/j.sder.2008.04.004 SilverbergJISimpsonELThyssenJPGooderhamMChanGFeeneyCBiswasPValdezHDiBonaventuraMNduakaCRojoREfficacy and safety of abrocitinib in patients with moderate-to-severe atopic dermatitis: a randomized clinical trialJAMA Dermatol202015686387310.1001/jamadermatol.2020.1406 BrunnerPMPavelABKhattriSLeonardAMalikKRoseSJim OnSVekariaASTraidl-HoffmannCSingerGKBaumDGilleaudeauPSullivan-WhalenMFuentes-DuculanJLiXZhengXEstradaYGarcetSWenHCGonzalezJCoatsICuetoINeumannAULebwohlMGKruegerJGGuttman-YasskyEBaseline IL-22 expression in patients with atopic dermatitis stratifies tissue responses to fezakinumabJ Allergy Clin Immunol20191431421541:CAS:528:DC%2BC1cXhslals7rP10.1016/j.jaci.2018.07.028 ShirleyMDupilumab: first global approvalDrugs201777111511211:CAS:528:DC%2BC2sXosVyntLs%3D10.1007/s40265-017-0768-3 Lilly (2022a) Lilly’s Lebrikizumab combined with topical corticosteroids showed significant improvements in disease severity for atopic dermatitis. https://investor.lilly.com/news-releases/news-release-details/lillys-lebrikizumab-combined-topical-corticosteroids-showed. Accessed 15 Aug 2022a ChiricozziABelloni FortinaAGalliEGirolomoniGNeriIRicciGRomanelliMPeroniDCurrent therapeutic paradigm in pediatric atopic dermatitis: practical guidance from a national expert panelAllergol Immunopathol2019471942061:STN:280:DC%2BB3czktVyksQ%3D%3D10.1016/j.aller.2018.06.008 DeeksEDDugganSAbrocitinib: first approvalDrugs202181214921571:CAS:528:DC%2BB38Xmtlaksbc%3D10.1007/s40265-021-01638-3 Lilly (2022b) Updates on OLUMIANT® (baricitinib) phase 3 lupus program and FDA review for atopic dermatitis. https://investor.lilly.com/news-releases/news-release-details/updates-olumiantr-baricitinib-phase-3-lupus-program-and-fda. Accessed 11 Nov 2022b SimpsonELBissonnetteREichenfieldLFGuttman-YasskyEKingBSilverbergJIBeckLABieberTReichKKabashimaKSeygerMSiegfriedEStinglGFeldmanSRMenterAvan de KerkhofPYosipovitchGPaulCMartelPDubost-BramaAArmstrongJChavdaRFreySJoubertYMilutinovicMParneixATeixeiraHDLinCYSunLKlekotkaPNickoloffBDutroncYMallbrisLJanesJMDeLozierAMNunesFPPallerASThe validated investigator global assessment for atopic dermatitis (vIGA-AD): the development and reliability testing of a novel clinical outcome measurement instrument for the severity of atopic dermatitisJ Am Acad Dermatol20208383984610.1016/j.jaad.2020.04.104 SimpsonELSinclairRFormanSWollenbergAAschoffRCorkMBieberTThyssenJPYosipovitchGFlohrCMagnoloNMaariCFeeneyCBiswasPTatulychSValdezHRojoREfficacy and safety of abrocitinib in adults and adolescents with moderate-to-severe atopic dermatitis (JADE MONO-1): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trialLancet20203962552661:CAS:528:DC%2BB3cXhsFSitr3I10.1016/S0140-6736(20)30732-7 WinthropKLCohenSBOral surveillance and JAK inhibitor safety: the theory of relativityNat Rev Rheumatol2022183013041:CAS:528:DC%2BB38XhtlehtLzO10.1038/s41584-022-00767-7 GittlerJKShemerASuárez-FariñasMFuentes-DuculanJGulewiczKJWangCQMitsuiHCardinaleIde GuzmanSCKruegerJGGuttman-YasskyEProgressive activation of T(H)2/T(H)22 cytokines and selective epidermal proteins characterizes acute and chronic atopic dermatitisJ Allergy Clin Immunol2012130134413541:CAS:528:DC%2BC38Xht1OjtrvO10.1016/j.jaci.2012.07.012 PopovicBBreedJReesDGGardenerMJVinallLMKempBSpoonerJKeenJMinterRUddinFColiceGWilkinsonTVaughanTMayRDStructural characterisation reveals mechanism of IL-13-neutralising monoclonal antibody tralokinumab as inhibition of binding to IL-13Rα1 and IL-13Rα2J Mol Biol20174292082191:CAS:528:DC%2BC28XitVyru7rN10.1016/j.jmb.2016.12.005 SilverbergJITothDBieberTAlexisAFElewskiBEPinkAEHijnenDJensenTNBangBOlsenCKKurbasicAWeidingerSTralokinumab plus topical corticosteroids for the treatment of moderate-to-severe atopic dermatitis: results from the double-blind, randomized, multicentre, placebo-controlled phase III ECZTRA 3 trialBr J Dermatol20211844504631:CAS:528:DC%2BB3MXmt1Oitbs%3D10.1111/bjd.19573 TokuraYHayanoSSubtypes of atopic dermatitis: from phenotype to endotypeAllergol Int20227114241:CAS:528:DC%2BB3MXitlCntrrF10.1016/j.alit.2021.07.003 PallerASSimpsonELSiegfriedECCorkMJWollenbergAArkwrightPDSoongWGonzalezMESchneiderLCSidburyRLockshinBMeltzerSWangZMannentLPAminNSunYLawsEAkinladeBDillonMKosloskiMPKamalMADubost-BramaAPatelNWeinreichDMYancopoulosGDO'MalleyJTBansalADupilumab in children aged 6 months to younger than 6 years with uncontrolled atopic dermatitis: a randomised, double-blind, placebo-controlled, phase 3 trialLancet20224009089191:CAS:528:DC%2BB38XisFyrsrfO10.1016/S0140-6736(22)01539-2 TsiogkaAKyriazopoulouMKontochristopoulosGNicolaidouEStratigosARigopoulosDGregoriouSThe JAK/STAT pathway and its selective inhibition in the treatment of atopic dermatitis: a systematic reviewJ Clin Med20221144311:CAS:528:DC%2BB38XitFejt7vE10.3390/jcm11154431 HawkesJEYanBYChanTCKruegerJGDiscovery of the IL-23/IL-17 signaling pathway and the treatment of psoriasisJ Immunol2018201160516131:CAS:528:DC%2BC1cXitVGhu7vJ10.4049/jimmunol.1800013 BlauveltAde Bruin-WellerMGooderhamMCatherJCWeismanJPariserDSimpsonELPappKAHongHC-HRubelDFoleyPPrensEGriffithsCEMEtohTPintoPHPujoRMSzepietowskiJCEttlerKKeményLZhuXAkinladeBHultschTMasteyVGadkariAEckertLAminNGrahamNMHPiro AS Paller (1421_CR73) 2020; 83 B Popovic (1421_CR78) 2017; 429 DS Bakker (1421_CR8) 2021; 147 S Duggan (1421_CR28) 2021; 81 A Chiricozzi (1421_CR21) 2019; 47 NA Gandhi (1421_CR34) 2016; 15 K Kabashima (1421_CR45) 2021; 8 1421_CR54 1421_CR53 A Rebane (1421_CR80) 2012; 129 A Blauvelt (1421_CR13) 2021; 157 Y Chen (1421_CR20) 2021; 7 CH Na (1421_CR64) 2020; 100 K Kabashima (1421_CR46) 2020; 383 AS Paller (1421_CR75) 2022; 400 E Guttman-Yassky (1421_CR36) 2018; 78 JL Thijs (1421_CR101) 2017; 140 SM Hoy (1421_CR44) 2022; 23 1421_CR67 1421_CR62 JD Hamilton (1421_CR39) 2021; 51 K Reich (1421_CR81) 2021; 397 T Werfel (1421_CR108) 2016; 138 JI Silverberg (1421_CR90) 2021; 184 DY Leung (1421_CR51) 2011; 127 DY Leung (1421_CR50) 2014; 134 PM Brunner (1421_CR15) 2019; 123 MD Howell (1421_CR43) 2019; 10 JK Gittler (1421_CR35) 2012; 130 T Bieber (1421_CR11) 2021; 384 A Tsiogka (1421_CR103) 2022; 11 H He (1421_CR42) 2019; 20 1421_CR31 R Chovatiya (1421_CR23) 2021; 148 ED Deeks (1421_CR26) 2021; 81 1421_CR38 EG Kang (1421_CR47) 2020; 75 Y Renert-Yuval (1421_CR83) 2020; 124 T Bieber (1421_CR10) 2022; 21 B Ungar (1421_CR106) 2021; 147 E Machura (1421_CR57) 2008; 19 Y Mizutani (1421_CR61) 2021; 30 A Wollenberg (1421_CR110) 2021; 184 N Yang (1421_CR111) 2022; 187 Y Handa (1421_CR40) 2019; 68 EL Simpson (1421_CR93) 2016; 375 T Nomura (1421_CR70) 2021; 148 TR Srinivas (1421_CR98) 2015; 99 O Massey (1421_CR58) 2021; 22 1421_CR6 EL Simpson (1421_CR95) 2020; 83 1421_CR7 A Labib (1421_CR48) 2022; 15 Y Renert-Yuval (1421_CR84) 2021; 147 1421_CR4 M Shirley (1421_CR86) 2017; 77 D Simon (1421_CR92) 2014; 69 1421_CR2 1421_CR3 1421_CR1 LC Tsoi (1421_CR104) 2019; 139 JI Silverberg (1421_CR91) 2022; 23 DM Peterson (1421_CR76) 2021; 10 A Datsi (1421_CR25) 2021; 76 Y Yuan (1421_CR112) 2022; 28 KL Winthrop (1421_CR109) 2022; 18 S Mastraftsi (1421_CR59) 2022; 11 JI Silverberg (1421_CR87) 2020; 145 S Noda (1421_CR69) 2016; 136 JE Hawkes (1421_CR41) 2018; 201 S Bylund (1421_CR18) 2020; 100 T Czarnowicki (1421_CR24) 2019; 143 M Ultsch (1421_CR105) 2013; 425 K Brar (1421_CR14) 2016; 16 Z Mikhak (1421_CR60) 2019; 139 JA Dudakov (1421_CR27) 2015; 33 M Furue (1421_CR32) 2018; 73 EL Simpson (1421_CR97) 2022; 158 H Lou (1421_CR56) 2017; 198 M Moyle (1421_CR63) 2019; 28 S Venkataramani (1421_CR107) 2018; 504 K Reich (1421_CR82) 2022; 400 Y Tokura (1421_CR102) 2022; 71 K Eyerich (1421_CR29) 2013; 68 M Galluzzo (1421_CR33) 2019; 12 H Schühlen (1421_CR85) 2014; 35 A Blauvelt (1421_CR12) 2017; 389 PM Brunner (1421_CR16) 2017; 139 T Bieber (1421_CR9) 2020; 75 1421_CR77 S Bylund (1421_CR19) 2020; 100 EL Simpson (1421_CR96) 2020; 396 S Swaidani (1421_CR100) 2019; 10 JM Oldhoff (1421_CR72) 2005; 60 A Chiricozzi (1421_CR22) 2020; 9 M Newsom (1421_CR68) 2020; 80 E Guttman-Yassky (1421_CR37) 2019; 143 X Li (1421_CR52) 2022; 18 D Ezzo (1421_CR30) 2017; 23 SM Langan (1421_CR49) 2020; 396 C Nakashima (1421_CR66) 2022; 71 JI Silverberg (1421_CR89) 2021; 35 A Akhavan (1421_CR5) 2008; 27 C Nakashima (1421_CR65) 2018; 27 PM Brunner (1421_CR17) 2019; 143 T Ratchataswan (1421_CR79) 2021; 9 JI Silverberg (1421_CR88) 2020; 156 T Nomura (1421_CR71) 2018; 30 EL Simpson (1421_CR94) 2020; 156 MK Lockhart (1421_CR55) 2022; 40 A Paller (1421_CR74) 2022; 6 M Sugaya (1421_CR99) 2020; 21 DJ Zhang (1421_CR113) 2022; 10 |
| References_xml | – volume: 9 start-page: 151 year: 2020 ident: 1421_CR22 publication-title: Immunotargets Ther doi: 10.2147/ITT.S260370 contributor: fullname: A Chiricozzi – volume: 35 start-page: 1562 year: 2021 ident: 1421_CR89 publication-title: J Eur Acad Dermatol Venereol doi: 10.1111/jdv.17218 contributor: fullname: JI Silverberg – volume: 80 start-page: 1041 year: 2020 ident: 1421_CR68 publication-title: Drugs doi: 10.1007/s40265-020-01335-7 contributor: fullname: M Newsom – volume: 10 start-page: 4 year: 2021 ident: 1421_CR76 publication-title: JAAD Case Rep doi: 10.1016/j.jdcr.2021.01.020 contributor: fullname: DM Peterson – volume: 375 start-page: 2335 year: 2016 ident: 1421_CR93 publication-title: N Engl J Med doi: 10.1056/NEJMoa1610020 contributor: fullname: EL Simpson – volume: 99 start-page: 17 year: 2015 ident: 1421_CR98 publication-title: Transplantation doi: 10.1097/TP.0000000000000581 contributor: fullname: TR Srinivas – volume: 100 start-page: adv00160 year: 2020 ident: 1421_CR19 publication-title: Acta Derm Venereol doi: 10.2340/00015555-3510 contributor: fullname: S Bylund – ident: 1421_CR3 – volume: 33 start-page: 747 year: 2015 ident: 1421_CR27 publication-title: Annu Rev Immunol doi: 10.1146/annurev-immunol-032414-112123 contributor: fullname: JA Dudakov – volume: 15 start-page: 1065 year: 2022 ident: 1421_CR48 publication-title: Clin Cosmet Investig Dermatol doi: 10.2147/CCID.S295672 contributor: fullname: A Labib – volume: 425 start-page: 1330 year: 2013 ident: 1421_CR105 publication-title: J Mol Biol doi: 10.1016/j.jmb.2013.01.024 contributor: fullname: M Ultsch – volume: 9 start-page: 1053 year: 2021 ident: 1421_CR79 publication-title: J Allergy Clin Immunol Pract doi: 10.1016/j.jaip.2020.11.034 contributor: fullname: T Ratchataswan – volume: 10 start-page: 2342 year: 2019 ident: 1421_CR43 publication-title: Front Immunol doi: 10.3389/fimmu.2019.02342 contributor: fullname: MD Howell – volume: 28 start-page: 756 year: 2019 ident: 1421_CR63 publication-title: Exp Dermatol doi: 10.1111/exd.13911 contributor: fullname: M Moyle – volume: 75 start-page: 54 year: 2020 ident: 1421_CR9 publication-title: Allergy doi: 10.1111/all.13954 contributor: fullname: T Bieber – volume: 8 start-page: 638325 year: 2021 ident: 1421_CR45 publication-title: Front Med (lausanne) doi: 10.3389/fmed.2021.638325 contributor: fullname: K Kabashima – volume: 140 start-page: 730 year: 2017 ident: 1421_CR101 publication-title: J Allergy Clin Immunol doi: 10.1016/j.jaci.2017.03.023 contributor: fullname: JL Thijs – volume: 35 start-page: 2055 year: 2014 ident: 1421_CR85 publication-title: Eur Heart J doi: 10.1093/eurheartj/ehu202 contributor: fullname: H Schühlen – ident: 1421_CR6 – volume: 134 start-page: 769 year: 2014 ident: 1421_CR50 publication-title: J Allergy Clin Immunol doi: 10.1016/j.jaci.2014.08.008 contributor: fullname: DY Leung – volume: 148 start-page: 1451 year: 2021 ident: 1421_CR70 publication-title: J Allergy Clin Immunol doi: 10.1016/j.jaci.2021.10.022 contributor: fullname: T Nomura – volume: 47 start-page: 194 year: 2019 ident: 1421_CR21 publication-title: Allergol Immunopathol doi: 10.1016/j.aller.2018.06.008 contributor: fullname: A Chiricozzi – volume: 127 start-page: 965 year: 2011 ident: 1421_CR51 publication-title: J Allergy Clin Immunol doi: 10.1016/j.jaci.2011.02.010 contributor: fullname: DY Leung – ident: 1421_CR53 – volume: 18 start-page: 301 year: 2022 ident: 1421_CR109 publication-title: Nat Rev Rheumatol doi: 10.1038/s41584-022-00767-7 contributor: fullname: KL Winthrop – volume: 16 start-page: 507 year: 2016 ident: 1421_CR14 publication-title: Expert Opin Biol Ther doi: 10.1517/14712598.2016.1135898 contributor: fullname: K Brar – volume: 40 start-page: 137 year: 2022 ident: 1421_CR55 publication-title: Dermatol Clin doi: 10.1016/j.det.2021.12.002 contributor: fullname: MK Lockhart – volume: 143 start-page: 155 year: 2019 ident: 1421_CR37 publication-title: J Allergy Clin Immunol doi: 10.1016/j.jaci.2018.08.02 contributor: fullname: E Guttman-Yassky – volume: 400 start-page: 908 year: 2022 ident: 1421_CR75 publication-title: Lancet doi: 10.1016/S0140-6736(22)01539-2 contributor: fullname: AS Paller – volume: 77 start-page: 1115 year: 2017 ident: 1421_CR86 publication-title: Drugs doi: 10.1007/s40265-017-0768-3 contributor: fullname: M Shirley – ident: 1421_CR67 – ident: 1421_CR38 – volume: 76 start-page: 2982 year: 2021 ident: 1421_CR25 publication-title: Allergy doi: 10.1111/all.14791 contributor: fullname: A Datsi – volume: 145 start-page: 173 year: 2020 ident: 1421_CR87 publication-title: J Allergy Clin Immunol doi: 10.1016/j.jaci.2019.08.013 contributor: fullname: JI Silverberg – volume: 147 start-page: 189 year: 2021 ident: 1421_CR8 publication-title: J Allergy Clin Immunol doi: 10.1016/j.jaci.2020.04.062 contributor: fullname: DS Bakker – volume: 15 start-page: 35 year: 2016 ident: 1421_CR34 publication-title: Nat Rev Drug Discov doi: 10.1038/nrd4624 contributor: fullname: NA Gandhi – volume: 198 start-page: 2543 year: 2017 ident: 1421_CR56 publication-title: J Immunol doi: 10.4049/jimmunol.1600126 contributor: fullname: H Lou – volume: 143 start-page: 1 year: 2019 ident: 1421_CR24 publication-title: J Allergy Clin Immunol doi: 10.1016/j.jaci.2018.10.032 contributor: fullname: T Czarnowicki – volume: 21 start-page: 1314 year: 2020 ident: 1421_CR99 publication-title: Int J Mol Sci doi: 10.3390/ijms21041314 contributor: fullname: M Sugaya – volume: 143 start-page: 142 year: 2019 ident: 1421_CR17 publication-title: J Allergy Clin Immunol doi: 10.1016/j.jaci.2018.07.028 contributor: fullname: PM Brunner – volume: 7 start-page: 1552 year: 2021 ident: 1421_CR20 publication-title: Engineering doi: 10.1016/j.eng.2020.06.029 contributor: fullname: Y Chen – volume: 73 start-page: 29 year: 2018 ident: 1421_CR32 publication-title: Allergy doi: 10.1111/all.13239 contributor: fullname: M Furue – volume: 11 start-page: 4431 year: 2022 ident: 1421_CR103 publication-title: J Clin Med doi: 10.3390/jcm11154431 contributor: fullname: A Tsiogka – volume: 11 start-page: 4639 year: 2022 ident: 1421_CR59 publication-title: J Clin Med doi: 10.3390/jcm11164639 contributor: fullname: S Mastraftsi – volume: 75 start-page: 950 year: 2020 ident: 1421_CR47 publication-title: Allergy doi: 10.1111/all.14050 contributor: fullname: EG Kang – volume: 156 start-page: 44 year: 2020 ident: 1421_CR94 publication-title: JAMA Dermatol doi: 10.1001/jamadermatol.2019.3336 contributor: fullname: EL Simpson – volume: 187 start-page: 828 year: 2022 ident: 1421_CR111 publication-title: Br J Dermatol doi: 10.1111/bjd.21776 contributor: fullname: N Yang – volume: 156 start-page: 863 year: 2020 ident: 1421_CR88 publication-title: JAMA Dermatol doi: 10.1001/jamadermatol.2020.1406 contributor: fullname: JI Silverberg – volume: 139 start-page: 1480 year: 2019 ident: 1421_CR104 publication-title: J Invest Dermatol doi: 10.1016/j.jid.2018.12.018 contributor: fullname: LC Tsoi – volume: 148 start-page: 927 year: 2021 ident: 1421_CR23 publication-title: J Allergy Clin Immunol doi: 10.1016/j.jaci.2021.08.009 contributor: fullname: R Chovatiya – volume: 184 start-page: 450 year: 2021 ident: 1421_CR90 publication-title: Br J Dermatol doi: 10.1111/bjd.19573 contributor: fullname: JI Silverberg – volume: 78 start-page: 872 year: 2018 ident: 1421_CR36 publication-title: J Am Acad Dermatol doi: 10.1016/j.jaad.2018.01.016 contributor: fullname: E Guttman-Yassky – volume: 51 start-page: 915 year: 2021 ident: 1421_CR39 publication-title: Clin Exp Allergy doi: 10.1111/cea.13954 contributor: fullname: JD Hamilton – volume: 157 start-page: 1047 year: 2021 ident: 1421_CR13 publication-title: JAMA Dermatol doi: 10.1001/jamadermatol.2021.3023 contributor: fullname: A Blauvelt – volume: 6 start-page: s29 year: 2022 ident: 1421_CR74 publication-title: Skin doi: 10.25251/skin.6.supp.s29 contributor: fullname: A Paller – volume: 124 start-page: 28 year: 2020 ident: 1421_CR83 publication-title: Ann Allergy Asthma Immunol doi: 10.1016/j.anai.2019.10.005 contributor: fullname: Y Renert-Yuval – volume: 100 start-page: 00160 year: 2020 ident: 1421_CR18 publication-title: Acta Derm Venereol doi: 10.2340/00015555-3510 contributor: fullname: S Bylund – ident: 1421_CR7 – volume: 81 start-page: 1657 year: 2021 ident: 1421_CR28 publication-title: Drugs doi: 10.1007/s40265-021-01583-1 contributor: fullname: S Duggan – volume: 384 start-page: 1101 year: 2021 ident: 1421_CR11 publication-title: N Engl J Med doi: 10.1056/NEJMoa2019380 contributor: fullname: T Bieber – volume: 22 start-page: 13655 year: 2021 ident: 1421_CR58 publication-title: Int J Mol Sci doi: 10.3390/ijms222413655 contributor: fullname: O Massey – ident: 1421_CR77 – ident: 1421_CR31 – volume: 396 start-page: 255 year: 2020 ident: 1421_CR96 publication-title: Lancet doi: 10.1016/S0140-6736(20)30732-7 contributor: fullname: EL Simpson – volume: 429 start-page: 208 year: 2017 ident: 1421_CR78 publication-title: J Mol Biol doi: 10.1016/j.jmb.2016.12.005 contributor: fullname: B Popovic – volume: 19 start-page: 37 year: 2008 ident: 1421_CR57 publication-title: Pediatr Allergy Immunol doi: 10.1111/j.1399-3038.2007.00586.x contributor: fullname: E Machura – volume: 389 start-page: 2287 year: 2017 ident: 1421_CR12 publication-title: Lancet doi: 10.1016/S0140-6736(17)31191-1 contributor: fullname: A Blauvelt – volume: 83 start-page: 839 year: 2020 ident: 1421_CR95 publication-title: J Am Acad Dermatol doi: 10.1016/j.jaad.2020.04.104 contributor: fullname: EL Simpson – ident: 1421_CR2 – volume: 383 start-page: 141 year: 2020 ident: 1421_CR46 publication-title: N Engl J Med doi: 10.1056/nejmoa1917006 contributor: fullname: K Kabashima – volume: 147 start-page: 1174 year: 2021 ident: 1421_CR84 publication-title: J Allergy Clin Immunol doi: 10.1016/j.jaci.2021.01.013 contributor: fullname: Y Renert-Yuval – volume: 123 start-page: 152 year: 2019 ident: 1421_CR15 publication-title: Ann Allergy Asthma Immunol doi: 10.1016/j.anai.2019.03.033 contributor: fullname: PM Brunner – ident: 1421_CR62 – volume: 68 start-page: 380 year: 2019 ident: 1421_CR40 publication-title: Allergol Int doi: 10.1016/j.alit.2018.12.011 contributor: fullname: Y Handa – volume: 158 start-page: 404 year: 2022 ident: 1421_CR97 publication-title: JAMA Dermatol doi: 10.1001/jamadermatol.2022.0029 contributor: fullname: EL Simpson – volume: 100 start-page: adv00165 year: 2020 ident: 1421_CR64 publication-title: Acta Derm Venereol doi: 10.2340/00015555-3515 contributor: fullname: CH Na – volume: 396 start-page: 354 year: 2020 ident: 1421_CR49 publication-title: Lancet doi: 10.1016/S0140-6736(20)31286-1 contributor: fullname: SM Langan – volume: 400 start-page: 273 year: 2022 ident: 1421_CR82 publication-title: Lancet doi: 10.1016/S0140-6736(22)01199-0 contributor: fullname: K Reich – volume: 139 start-page: S96 year: 2019 ident: 1421_CR60 publication-title: J Invest Dermatol doi: 10.1016/j.jid.2019.03.636 contributor: fullname: Z Mikhak – volume: 18 start-page: 12 year: 2022 ident: 1421_CR52 publication-title: Allergy Asthma Clin Immunol doi: 10.1186/s13223-022-00652-8 contributor: fullname: X Li – volume: 201 start-page: 1605 year: 2018 ident: 1421_CR41 publication-title: J Immunol doi: 10.4049/jimmunol.1800013 contributor: fullname: JE Hawkes – volume: 30 start-page: 419 year: 2018 ident: 1421_CR71 publication-title: Int Immunol doi: 10.1093/intimm/dxy015 contributor: fullname: T Nomura – volume: 147 start-page: 394 year: 2021 ident: 1421_CR106 publication-title: J Allergy Clin Immunol doi: 10.1016/j.jaci.2020.04.055 contributor: fullname: B Ungar – volume: 23 start-page: S124 year: 2017 ident: 1421_CR30 publication-title: Am J Manag Care contributor: fullname: D Ezzo – volume: 23 start-page: 1 year: 2022 ident: 1421_CR91 publication-title: Am J Clin Dermatol doi: 10.1007/s40257-021-00639-y contributor: fullname: JI Silverberg – volume: 20 start-page: 181 year: 2019 ident: 1421_CR42 publication-title: Am J Clin Dermatol doi: 10.1007/s40257-018-0413-2 contributor: fullname: H He – volume: 130 start-page: 1344 year: 2012 ident: 1421_CR35 publication-title: J Allergy Clin Immunol doi: 10.1016/j.jaci.2012.07.012 contributor: fullname: JK Gittler – volume: 27 start-page: 327 year: 2018 ident: 1421_CR65 publication-title: Exp Dermatol doi: 10.1111/exd.13533 contributor: fullname: C Nakashima – volume: 12 start-page: 311 year: 2019 ident: 1421_CR33 publication-title: Clin Cosmet Investig Dermatol doi: 10.2147/CCID.S165605 contributor: fullname: M Galluzzo – volume: 397 start-page: 2169 year: 2021 ident: 1421_CR81 publication-title: Lancet doi: 10.1016/S0140-6736(21)00589-4 contributor: fullname: K Reich – volume: 83 start-page: 1282 year: 2020 ident: 1421_CR73 publication-title: J Am Acad Dermatol doi: 10.1016/j.jaad.2020.06.054 contributor: fullname: AS Paller – volume: 30 start-page: 1754 year: 2021 ident: 1421_CR61 publication-title: Exp Dermatol doi: 10.1111/exd.14425 contributor: fullname: Y Mizutani – volume: 71 start-page: 40 year: 2022 ident: 1421_CR66 publication-title: Allergol Int doi: 10.1016/j.alit.2021.10.004 contributor: fullname: C Nakashima – volume: 71 start-page: 14 year: 2022 ident: 1421_CR102 publication-title: Allergol Int doi: 10.1016/j.alit.2021.07.003 contributor: fullname: Y Tokura – volume: 504 start-page: 19 year: 2018 ident: 1421_CR107 publication-title: Biochem Biophys Res Commun doi: 10.1016/j.bbrc.2018.08.064 contributor: fullname: S Venkataramani – ident: 1421_CR1 – volume: 129 start-page: 1297 year: 2012 ident: 1421_CR80 publication-title: J Allergy Clin Immunol doi: 10.1016/j.jaci.2012.02.020 contributor: fullname: A Rebane – volume: 81 start-page: 2149 year: 2021 ident: 1421_CR26 publication-title: Drugs doi: 10.1007/s40265-021-01638-3 contributor: fullname: ED Deeks – volume: 23 start-page: 409 year: 2022 ident: 1421_CR44 publication-title: Am J Clin Dermatol doi: 10.1007/s40257-022-00684-1 contributor: fullname: SM Hoy – volume: 28 start-page: 596 year: 2022 ident: 1421_CR112 publication-title: Trend Mol Med doi: 10.1016/j.molmed.2022.04.010 contributor: fullname: Y Yuan – ident: 1421_CR54 – volume: 69 start-page: 46 year: 2014 ident: 1421_CR92 publication-title: Allergy doi: 10.1111/all.12339 contributor: fullname: D Simon – volume: 10 start-page: 1293 year: 2019 ident: 1421_CR100 publication-title: Front Immunol doi: 10.3389/fimmu.2019.01293 contributor: fullname: S Swaidani – volume: 139 start-page: S65 issue: 4S year: 2017 ident: 1421_CR16 publication-title: J Allergy Clin Immunol doi: 10.1016/j.jaci.2017.01.011 contributor: fullname: PM Brunner – volume: 138 start-page: 336 year: 2016 ident: 1421_CR108 publication-title: J Allergy Clin Immunol doi: 10.1016/j.jaci.2016.06.010 contributor: fullname: T Werfel – volume: 184 start-page: 437 year: 2021 ident: 1421_CR110 publication-title: Br J Dermatol doi: 10.1111/bjd.19574 contributor: fullname: A Wollenberg – volume: 10 year: 2022 ident: 1421_CR113 publication-title: Front Pediatr doi: 10.3389/fped.2022.777992 contributor: fullname: DJ Zhang – volume: 27 start-page: 151 year: 2008 ident: 1421_CR5 publication-title: Semin Cutan Med Surg doi: 10.1016/j.sder.2008.04.004 contributor: fullname: A Akhavan – ident: 1421_CR4 – volume: 60 start-page: 693 year: 2005 ident: 1421_CR72 publication-title: Allergy doi: 10.1111/j.1398-9995.2005.00791.x contributor: fullname: JM Oldhoff – volume: 68 start-page: 974 year: 2013 ident: 1421_CR29 publication-title: Allergy doi: 10.1111/all.12184 contributor: fullname: K Eyerich – volume: 136 start-page: S40 year: 2016 ident: 1421_CR69 publication-title: J Invest Dermatol doi: 10.1016/j.jid.2016.02.253 contributor: fullname: S Noda – volume: 21 start-page: 21 year: 2022 ident: 1421_CR10 publication-title: Nat Rev Drug Discov doi: 10.1038/s41573-021-00266-6 contributor: fullname: T Bieber |
| SSID | ssj0036555 |
| Score | 2.4087481 |
| SecondaryResourceType | review_article |
| Snippet | Although atopic dermatitis (AD) is primarily a Th2-driven disease, it shows high heterogeneity with additional variable contributions of the Th22, Th17, and... |
| SourceID | proquest crossref pubmed springer |
| SourceType | Aggregation Database Index Database Publisher |
| StartPage | 894 |
| SubjectTerms | Medicine Pharmacology/Toxicology Pharmacy Review |
| Title | Targeting cytokines and signaling molecules related to immune pathways in atopic dermatitis: therapeutic implications and challenges |
| URI | https://link.springer.com/article/10.1007/s12272-022-01421-2 https://www.ncbi.nlm.nih.gov/pubmed/36462097 https://search.proquest.com/docview/2746394133 |
| Volume | 45 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV3dS9xAEB-sQulLq7bVs-2xheJLbyXZj3z07SyeYlF8uAP7FLIfgUPMSZOjXJ_9wzu7SRrLieBrSHYI8_VbZn4zAF84D0WM92OqwkRTYQtOE9Q71SqwSaxjk1tHcL64jM5m4vxaXvc8bt_s3lUkfaDuuW6MxYy65nNE9SykGHe3MPc4b9wan_78cdIFYB5Jv-wUszmniNfTlivz-Cn_56M1kLlWIPV5Z_IGph17p2k3uTla1upI_1kf5vicX9qG1y0OJePGcHZgw5a78PKirbTvwuFVM9N6NSLTnqJVjcghueqnXa_ewv3U95KjXKJX9eLGtdGTvDTEdYbkjuxObpsVvPjcM2esIfWCzB0xxRK3Efl3vqrIvCR4_7-ba2JsA6Pn1TfygB6GX_S1di9Bd4tgqncwm5xMv5_RdrUD1VzENZVK8xyBfa5lKnSgQ2OZcqPl3BZVNxVNqkAViEUQvkpjdcEwDic8MkUUiUBJ_h42y0Vp94EkXKQ6sVabKBEG1R0WeZCkQpq4SKVVA_jaKTi7ayZ4ZP2sZqeBDDWQeQ1kbACfOxvI0NFc9SQv7WJZZXh9RzSHOZ8PYK8xjn_n8UhELEjjAYw6TWdtLKieEHbwvNc_wCvmjMU303yEzfrX0n5CSFSrIbrA5Pj4cti6whBezNj4L1L2Bbc |
| link.rule.ids | 314,780,784,27924,27925,41081,41523,42150,42592,52111,52234 |
| linkProvider | Springer Nature |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1Ni9RAEC1kBfUiOuu6o6u2IHNxGpL-yMfeBnEZdWbZwwzMrUl_BAYxs2yyyNz94VZ3ErMysuA1JOnD6656TdWrB_CB81ikeD-mOs4MFa7kNEPcqdGRy1KT2sJ5gfPyMpmvxdeN3HSisLrvdu9LkiFSD2I3xlJGffc50noWUwy8D3HH5d63YM1mffzliQxep5jMOUW6nndSmX__4-90dMAxD-qjIe1cPIOnHV8ksxbg5_DAVSN4tOwq4iOYXLWzp_dTshqkVPWUTMjVMJV6fwy_VqHnGxchZt_svvt2d1JUlvgOjsKL0smP1ioXnweFi7Ok2ZGtF5A44p2Lfxb7mmwrgvf0660h1rV0d1ufkzsyLvxiqImHFUxv2FK_gPXF59WnOe0sGKjhIm2o1IYXSMALI3NhIhNbx7QfAefdTv30MqkjXSJnQJoprTMlw3iZ8cSWSSIiLfkJHFW7yp0CybjITeacsUkmLOISl0WU5ULatMyl02P42COhrttJG2qYqexxU4ibCrgpNob3PVgKD4SvchSV293WCq_ZyLowN_MxvGxR_PM_noiERXk6hmkPq-rObH3PYq_-7_V38Hi-Wi7U4svlt9fwhPntFhpgzuCoubl1b5DGNPpt2LW_AXDG6jw |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1La9wwEB5CCqGX0iR9bJO0KoRcuiK2Hn70FtouSZqEPexCbsJ6GJYQ7xI7hL33h3ck23FKSqFXI0uHT9J8Yub7BuCQ81ik-D6mOs4MFa7kNEPcqdGRy1KT2sJ5gfPlVXI6F-fX8vqJij9Uu_cpyVbT4F2aquZ4ZcvjQfjGWMqor0RHis9iipfwCx-K_E6fs5P-LuaJDH1PMbBzitQ972Qzf5_jz9D0jG8-y5WGEDR5Da867khOWrC3YcNVO7B12WXHd-Bo2vpQr8dkNsiq6jE5ItPBoXq9C79mof4bFyFm3SxvfOk7KSpLfDVH4QXq5LZtm4vfg9rFWdIsycKLSRzxXYwfinVNFhXBN_tqYYh1LfVd1F_JE0kX_jHkx8MKpm_eUr-B-eTH7Nsp7doxUMNF2lCpDS-QjBdG5sJEJraOaW8H5zufeiczqSNdIn9AyimtMyXDuzPjiS2TRERa8rewWS0r9x5IxkVuMueMTTJhEZe4LKIsF9KmZS6dHsGXHgm1al031OCv7HFTiJsKuCk2gs89WAoPh894FJVb3tcKn9zIwDBO8xG8a1F8nI8nImFRno5g3MOquvNb_2OxD_83_BNsTb9P1MXZ1c89eMn8bgu1MPuw2dzduwNkNI3-GDbtb9fC7ng |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Targeting+cytokines+and+signaling+molecules+related+to+immune+pathways+in+atopic+dermatitis%3A+therapeutic+implications+and+challenges&rft.jtitle=Archives+of+pharmacal+research&rft.au=Kim%2C+Hyung-Ook&rft.date=2022-12-01&rft.eissn=1976-3786&rft.volume=45&rft.issue=12&rft.spage=894&rft_id=info:doi/10.1007%2Fs12272-022-01421-2&rft_id=info%3Apmid%2F36462097&rft.externalDocID=36462097 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0253-6269&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0253-6269&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0253-6269&client=summon |